Review



massarray platform  (agena bioscience)


Bioz Verified Symbol agena bioscience is a verified supplier
Bioz Manufacturer Symbol agena bioscience manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    agena bioscience massarray platform
    MiR‐9‐1 is downregulated by promoter methylation in nasopharyngeal carcinoma (NPC). A, CpG islands in miR‐9‐1. The transcription start site (TSS) is indicated by a curved arrow. The regions analyzed by methylation‐specific PCR (MSP) and <t>MassARRAY</t> are shown. B, Relative miR‐9‐1 expression in normal nasopharyngeal NP69 cells and NPC cell lines. Glyceraldehyde‐3‐phosphate dehydrogenase ( GAPDH ) was used as the endogenous control. C, Relative miR‐9‐1 expression in 11 normal nasopharyngeal tissues (N) and 16 NPC tissues (T). U6 was used as the endogenous control. * P < .05. D, Quantitative MassARRAY methylation analysis of miR‐9‐1 in normal tissues (NT), NPC tissue (P), NP69 cell lines, NPC cell lines. E, F, MSP analysis of miR‐9‐1 promoter methylation in NPC cell lines and tissue specimens. M, methylated; U, unmethylated; L, marker; 1‐14, NPC tissue specimen numbers. G, Demethylation treatment with 5‐Aza‐2’‐deoxycytidine (DAC) restored the expression of miR‐9‐1 in NPC cell lines
    Massarray Platform, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 2219 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+methylation+platform/Methylation/pmc08486208-91-2-4
    Average 96 stars, based on 2219 article reviews
    massarray platform - by Bioz Stars, 2026-10
    96/100 stars

    Images

    1) Product Images from "Methylation‐associated silencing of miR‐9‐1 promotes nasopharyngeal carcinoma progression and glycolysis via HK2"

    Article Title: Methylation‐associated silencing of miR‐9‐1 promotes nasopharyngeal carcinoma progression and glycolysis via HK2

    Journal: Cancer Science

    doi: 10.1111/cas.15103

    MiR‐9‐1 is downregulated by promoter methylation in nasopharyngeal carcinoma (NPC). A, CpG islands in miR‐9‐1. The transcription start site (TSS) is indicated by a curved arrow. The regions analyzed by methylation‐specific PCR (MSP) and MassARRAY are shown. B, Relative miR‐9‐1 expression in normal nasopharyngeal NP69 cells and NPC cell lines. Glyceraldehyde‐3‐phosphate dehydrogenase ( GAPDH ) was used as the endogenous control. C, Relative miR‐9‐1 expression in 11 normal nasopharyngeal tissues (N) and 16 NPC tissues (T). U6 was used as the endogenous control. * P < .05. D, Quantitative MassARRAY methylation analysis of miR‐9‐1 in normal tissues (NT), NPC tissue (P), NP69 cell lines, NPC cell lines. E, F, MSP analysis of miR‐9‐1 promoter methylation in NPC cell lines and tissue specimens. M, methylated; U, unmethylated; L, marker; 1‐14, NPC tissue specimen numbers. G, Demethylation treatment with 5‐Aza‐2’‐deoxycytidine (DAC) restored the expression of miR‐9‐1 in NPC cell lines
    Figure Legend Snippet: MiR‐9‐1 is downregulated by promoter methylation in nasopharyngeal carcinoma (NPC). A, CpG islands in miR‐9‐1. The transcription start site (TSS) is indicated by a curved arrow. The regions analyzed by methylation‐specific PCR (MSP) and MassARRAY are shown. B, Relative miR‐9‐1 expression in normal nasopharyngeal NP69 cells and NPC cell lines. Glyceraldehyde‐3‐phosphate dehydrogenase ( GAPDH ) was used as the endogenous control. C, Relative miR‐9‐1 expression in 11 normal nasopharyngeal tissues (N) and 16 NPC tissues (T). U6 was used as the endogenous control. * P < .05. D, Quantitative MassARRAY methylation analysis of miR‐9‐1 in normal tissues (NT), NPC tissue (P), NP69 cell lines, NPC cell lines. E, F, MSP analysis of miR‐9‐1 promoter methylation in NPC cell lines and tissue specimens. M, methylated; U, unmethylated; L, marker; 1‐14, NPC tissue specimen numbers. G, Demethylation treatment with 5‐Aza‐2’‐deoxycytidine (DAC) restored the expression of miR‐9‐1 in NPC cell lines

    Techniques Used: Methylation, Expressing, Marker

    Related Articles

    Polymerase Chain Reaction:

    Article Title: DNA Methylation in Gastric Cancer and Preneoplastic Lesions: Emerging Insights and Future Directions.
    Article Snippet: .. The converted DNA can be analyzed through different PCR-based methods: (i) methylation-specific PCR (MSP) [82,83]; (ii) methylation-sensitive high-resolution technology (MS-HRM) [81,84]; (iii) bisulfite sequencing PCR [76]; (iv) bisulfite pyrosequencing [85–87]; (v) droplet digital PCR (ddPCR) [88–90]; (vi) Epityper by Agena Bioscience (Sequenom, San Diego, CA) [91]. ..

    Article Title: DNA Methylation in Gastric Cancer and Preneoplastic Lesions: Emerging Insights and Future Directions
    Article Snippet: .. The converted DNA can be analyzed through different PCR-based methods: (i) methylation-specific PCR (MSP) [ , ]; (ii) methylation-sensitive high-resolution technology (MS-HRM) [ , ]; (iii) bisulfite sequencing PCR [ ]; (iv) bisulfite pyrosequencing [ , , ]; (v) droplet digital PCR (ddPCR) [ , , ]; (vi) Epityper by Agena Bioscience (Sequenom, San Diego, CA) [ ]. ..

    Methylation:

    Article Title: DNA Methylation in Gastric Cancer and Preneoplastic Lesions: Emerging Insights and Future Directions.
    Article Snippet: .. The converted DNA can be analyzed through different PCR-based methods: (i) methylation-specific PCR (MSP) [82,83]; (ii) methylation-sensitive high-resolution technology (MS-HRM) [81,84]; (iii) bisulfite sequencing PCR [76]; (iv) bisulfite pyrosequencing [85–87]; (v) droplet digital PCR (ddPCR) [88–90]; (vi) Epityper by Agena Bioscience (Sequenom, San Diego, CA) [91]. ..

    Article Title: DNA Methylation in Gastric Cancer and Preneoplastic Lesions: Emerging Insights and Future Directions
    Article Snippet: .. The converted DNA can be analyzed through different PCR-based methods: (i) methylation-specific PCR (MSP) [ , ]; (ii) methylation-sensitive high-resolution technology (MS-HRM) [ , ]; (iii) bisulfite sequencing PCR [ ]; (iv) bisulfite pyrosequencing [ , , ]; (v) droplet digital PCR (ddPCR) [ , , ]; (vi) Epityper by Agena Bioscience (Sequenom, San Diego, CA) [ ]. ..

    Article Title: Differential miRNA expression during replicative senescence of dental pulp stem cells with potential for forensic age assessment.
    Article Snippet: .. Freire-Aradas A, Phillips C, Mosquera-Miguel A, Girón-Santamaría L, Gómez-Tato A, Casares De Cal M, et al. Development of a methylation marker set for forensic age estimation using analysis of public methylation data and the Agena Bioscience EpiTYPER system. ..

    Methylation Sequencing:

    Article Title: DNA Methylation in Gastric Cancer and Preneoplastic Lesions: Emerging Insights and Future Directions.
    Article Snippet: .. The converted DNA can be analyzed through different PCR-based methods: (i) methylation-specific PCR (MSP) [82,83]; (ii) methylation-sensitive high-resolution technology (MS-HRM) [81,84]; (iii) bisulfite sequencing PCR [76]; (iv) bisulfite pyrosequencing [85–87]; (v) droplet digital PCR (ddPCR) [88–90]; (vi) Epityper by Agena Bioscience (Sequenom, San Diego, CA) [91]. ..

    Article Title: DNA Methylation in Gastric Cancer and Preneoplastic Lesions: Emerging Insights and Future Directions
    Article Snippet: .. The converted DNA can be analyzed through different PCR-based methods: (i) methylation-specific PCR (MSP) [ , ]; (ii) methylation-sensitive high-resolution technology (MS-HRM) [ , ]; (iii) bisulfite sequencing PCR [ ]; (iv) bisulfite pyrosequencing [ , , ]; (v) droplet digital PCR (ddPCR) [ , , ]; (vi) Epityper by Agena Bioscience (Sequenom, San Diego, CA) [ ]. ..

    Digital PCR:

    Article Title: DNA Methylation in Gastric Cancer and Preneoplastic Lesions: Emerging Insights and Future Directions.
    Article Snippet: .. The converted DNA can be analyzed through different PCR-based methods: (i) methylation-specific PCR (MSP) [82,83]; (ii) methylation-sensitive high-resolution technology (MS-HRM) [81,84]; (iii) bisulfite sequencing PCR [76]; (iv) bisulfite pyrosequencing [85–87]; (v) droplet digital PCR (ddPCR) [88–90]; (vi) Epityper by Agena Bioscience (Sequenom, San Diego, CA) [91]. ..

    Article Title: DNA Methylation in Gastric Cancer and Preneoplastic Lesions: Emerging Insights and Future Directions
    Article Snippet: .. The converted DNA can be analyzed through different PCR-based methods: (i) methylation-specific PCR (MSP) [ , ]; (ii) methylation-sensitive high-resolution technology (MS-HRM) [ , ]; (iii) bisulfite sequencing PCR [ ]; (iv) bisulfite pyrosequencing [ , , ]; (v) droplet digital PCR (ddPCR) [ , , ]; (vi) Epityper by Agena Bioscience (Sequenom, San Diego, CA) [ ]. ..

    Marker:

    Article Title: Differential miRNA expression during replicative senescence of dental pulp stem cells with potential for forensic age assessment.
    Article Snippet: .. Freire-Aradas A, Phillips C, Mosquera-Miguel A, Girón-Santamaría L, Gómez-Tato A, Casares De Cal M, et al. Development of a methylation marker set for forensic age estimation using analysis of public methylation data and the Agena Bioscience EpiTYPER system. ..

    other:

    Article Title: Chronic heart failure and GPX3 promoter methylation: A clinical-epigenetic analysis.
    Article Snippet: Background: Selenoprotein GPX3 is linked to Chronic Heart Failure (CHF), but its promoter methylation patterns in CHF remain unclear.. Objective: To explore CpG methylation in the GPX3 promoter region and its association with clinical parameters in CHF.. Methods: Twenty CHF patients and twenty healthy controls were included.

    DNA Methylation Assay:

    Article Title: ADAMTS9-AS2 acts as an epigenetic brake to constrain DNMT3B-mediated CADM2 silencing in esophageal squamous cell carcinoma metastasis
    Article Snippet: .. Targeted DNA methylation validation was performed using the MassARRAY EpiTYPER platform (Agena Bioscience) on 24 paired ESCC tumor and adjacent normal tissues. .. Genomic DNA underwent bisulfite conversion (EZ DNA Methylation-Lightning Kit, Zymo Research), followed by PCR amplification of the CADM2 locus flanking the cg03455765 region.

    Biomarker Discovery:

    Article Title: ADAMTS9-AS2 acts as an epigenetic brake to constrain DNMT3B-mediated CADM2 silencing in esophageal squamous cell carcinoma metastasis
    Article Snippet: .. Targeted DNA methylation validation was performed using the MassARRAY EpiTYPER platform (Agena Bioscience) on 24 paired ESCC tumor and adjacent normal tissues. .. Genomic DNA underwent bisulfite conversion (EZ DNA Methylation-Lightning Kit, Zymo Research), followed by PCR amplification of the CADM2 locus flanking the cg03455765 region.



    Similar Products

    massarray methylation platform  (agena bioscience)
    96
    agena bioscience massarray methylation platform
    Massarray Methylation Platform, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+methylation+platform/Methylation/pmc07507324-118-16-19
    Average 96 stars, based on 1 article reviews
    massarray methylation platform - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    dna methylation at faim2 promoter sequenom massarray platform  (Sequenom)
    90
    Sequenom dna methylation at faim2 promoter sequenom massarray platform
    Dna Methylation At Faim2 Promoter Sequenom Massarray Platform, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+methylation+platform/dna+methylation+at+faim2+promoter+sequenom+massarray+platform/pmc09263076-9-61-66
    Average 90 stars, based on 1 article reviews
    dna methylation at faim2 promoter sequenom massarray platform - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    massarray platform  (agena bioscience)
    96
    agena bioscience massarray platform
    MiR‐9‐1 is downregulated by promoter methylation in nasopharyngeal carcinoma (NPC). A, CpG islands in miR‐9‐1. The transcription start site (TSS) is indicated by a curved arrow. The regions analyzed by methylation‐specific PCR (MSP) and <t>MassARRAY</t> are shown. B, Relative miR‐9‐1 expression in normal nasopharyngeal NP69 cells and NPC cell lines. Glyceraldehyde‐3‐phosphate dehydrogenase ( GAPDH ) was used as the endogenous control. C, Relative miR‐9‐1 expression in 11 normal nasopharyngeal tissues (N) and 16 NPC tissues (T). U6 was used as the endogenous control. * P < .05. D, Quantitative MassARRAY methylation analysis of miR‐9‐1 in normal tissues (NT), NPC tissue (P), NP69 cell lines, NPC cell lines. E, F, MSP analysis of miR‐9‐1 promoter methylation in NPC cell lines and tissue specimens. M, methylated; U, unmethylated; L, marker; 1‐14, NPC tissue specimen numbers. G, Demethylation treatment with 5‐Aza‐2’‐deoxycytidine (DAC) restored the expression of miR‐9‐1 in NPC cell lines
    Massarray Platform, supplied by agena bioscience, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+methylation+platform/Methylation/pmc08486208-91-2-4
    Average 96 stars, based on 1 article reviews
    massarray platform - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    quantitative methylation analysis based on sequenom massarray platform  (Sequenom)
    90
    Sequenom quantitative methylation analysis based on sequenom massarray platform
    MiR‐9‐1 is downregulated by promoter methylation in nasopharyngeal carcinoma (NPC). A, CpG islands in miR‐9‐1. The transcription start site (TSS) is indicated by a curved arrow. The regions analyzed by methylation‐specific PCR (MSP) and <t>MassARRAY</t> are shown. B, Relative miR‐9‐1 expression in normal nasopharyngeal NP69 cells and NPC cell lines. Glyceraldehyde‐3‐phosphate dehydrogenase ( GAPDH ) was used as the endogenous control. C, Relative miR‐9‐1 expression in 11 normal nasopharyngeal tissues (N) and 16 NPC tissues (T). U6 was used as the endogenous control. * P < .05. D, Quantitative MassARRAY methylation analysis of miR‐9‐1 in normal tissues (NT), NPC tissue (P), NP69 cell lines, NPC cell lines. E, F, MSP analysis of miR‐9‐1 promoter methylation in NPC cell lines and tissue specimens. M, methylated; U, unmethylated; L, marker; 1‐14, NPC tissue specimen numbers. G, Demethylation treatment with 5‐Aza‐2’‐deoxycytidine (DAC) restored the expression of miR‐9‐1 in NPC cell lines
    Quantitative Methylation Analysis Based On Sequenom Massarray Platform, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+methylation+platform/massarray+quantitative+methylation+analysis/10__1158_slash_1541___7786__mcr___20___0933-187-20-19
    Average 90 stars, based on 1 article reviews
    quantitative methylation analysis based on sequenom massarray platform - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    massarray quantitative methylation analysis platform  (Sequenom)
    90
    Sequenom massarray quantitative methylation analysis platform
    During transforming growth factor β1 (TGFβ1)-induced epithelial-to-mesenchymal transition (EMT), stomatin was downregulated through <t>methylation-dependent</t> transcription mechanism. (A) Real-time polymerase chain reaction (PCR) was performed to validate the transcriptional change of stomatin identified in the microarray. **, P<0.001; (B) Two CpG islands spanning from −768 to −223 bp and from −143 to +122 bp upstream of STOM gene were identified by EMBOSS cpgplot program (upper). Schematic representation of −768/−223 and −143/+122 (marked with the grey square) CpG islands in the upstream of stomatin gene (lower). Red box marked the exon. The translation start site was position +1; (C) Measuring stomatin promoter methylation levels by Sequenom <t>MassARRAY</t> assay; (D) Sequenom MassARRAY analysis of methylation percentages of CpG sites at the stomatin promoter. The top panel showed the methylation percentages of 30 sites in human bronchial epithelial (HBE) and A549 cells. Dots with different color depths represent different methylation status. Dark dots represent high degrees of methylation. Light dots represent low degrees of methylation. The methylation percentages of 30 CpG sites were compared by two-tailed paired Student’s t test. In line graph, each dot represents an individual CpG dinucleotide. Green dots represent CpG dinucleotides in HBE cells. Red dots represent CpG sites in A549 cells. The corresponding detection sites were connected in a straight line. Real-time PCR was performed to evaluate the expression of stomatin in HBE and A549 cells (P<0.01); (E) The same sequenom MassArray and statistical analyses were also implemented to assess the methylation status of the indicated promoter region of stomatin in A549 and A549-5Aza cells (P<0.01); (F) A549 cells were exposed to TGFβ1 (5 ng/mL) for 2 d or 5 d with or without 5-Aza. Expression of DNMT3A and stomatin was analyzed by western blotting. β-actin was used as a loading control; (G) Sequenom MassArray analysis was implemented to assess the stomatin promoter methylation levels in A549, A549-TGFβ1, and A549-TGFβ1/5-Aza cells (P=0.005, P=0.004, respectively).
    Massarray Quantitative Methylation Analysis Platform, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+methylation+platform/massarray+quantitative+methylation+analysis/pmc06955161-113-10-9
    Average 90 stars, based on 1 article reviews
    massarray quantitative methylation analysis platform - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    massarray methylation platform  (Sequenom)
    90
    Sequenom massarray methylation platform
    During transforming growth factor β1 (TGFβ1)-induced epithelial-to-mesenchymal transition (EMT), stomatin was downregulated through <t>methylation-dependent</t> transcription mechanism. (A) Real-time polymerase chain reaction (PCR) was performed to validate the transcriptional change of stomatin identified in the microarray. **, P<0.001; (B) Two CpG islands spanning from −768 to −223 bp and from −143 to +122 bp upstream of STOM gene were identified by EMBOSS cpgplot program (upper). Schematic representation of −768/−223 and −143/+122 (marked with the grey square) CpG islands in the upstream of stomatin gene (lower). Red box marked the exon. The translation start site was position +1; (C) Measuring stomatin promoter methylation levels by Sequenom <t>MassARRAY</t> assay; (D) Sequenom MassARRAY analysis of methylation percentages of CpG sites at the stomatin promoter. The top panel showed the methylation percentages of 30 sites in human bronchial epithelial (HBE) and A549 cells. Dots with different color depths represent different methylation status. Dark dots represent high degrees of methylation. Light dots represent low degrees of methylation. The methylation percentages of 30 CpG sites were compared by two-tailed paired Student’s t test. In line graph, each dot represents an individual CpG dinucleotide. Green dots represent CpG dinucleotides in HBE cells. Red dots represent CpG sites in A549 cells. The corresponding detection sites were connected in a straight line. Real-time PCR was performed to evaluate the expression of stomatin in HBE and A549 cells (P<0.01); (E) The same sequenom MassArray and statistical analyses were also implemented to assess the methylation status of the indicated promoter region of stomatin in A549 and A549-5Aza cells (P<0.01); (F) A549 cells were exposed to TGFβ1 (5 ng/mL) for 2 d or 5 d with or without 5-Aza. Expression of DNMT3A and stomatin was analyzed by western blotting. β-actin was used as a loading control; (G) Sequenom MassArray analysis was implemented to assess the stomatin promoter methylation levels in A549, A549-TGFβ1, and A549-TGFβ1/5-Aza cells (P=0.005, P=0.004, respectively).
    Massarray Methylation Platform, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/massarray+methylation+platform/massarray+quantitative+methylation+analysis/pm29385306-106-26-25
    Average 90 stars, based on 1 article reviews
    massarray methylation platform - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    MiR‐9‐1 is downregulated by promoter methylation in nasopharyngeal carcinoma (NPC). A, CpG islands in miR‐9‐1. The transcription start site (TSS) is indicated by a curved arrow. The regions analyzed by methylation‐specific PCR (MSP) and MassARRAY are shown. B, Relative miR‐9‐1 expression in normal nasopharyngeal NP69 cells and NPC cell lines. Glyceraldehyde‐3‐phosphate dehydrogenase ( GAPDH ) was used as the endogenous control. C, Relative miR‐9‐1 expression in 11 normal nasopharyngeal tissues (N) and 16 NPC tissues (T). U6 was used as the endogenous control. * P < .05. D, Quantitative MassARRAY methylation analysis of miR‐9‐1 in normal tissues (NT), NPC tissue (P), NP69 cell lines, NPC cell lines. E, F, MSP analysis of miR‐9‐1 promoter methylation in NPC cell lines and tissue specimens. M, methylated; U, unmethylated; L, marker; 1‐14, NPC tissue specimen numbers. G, Demethylation treatment with 5‐Aza‐2’‐deoxycytidine (DAC) restored the expression of miR‐9‐1 in NPC cell lines

    Journal: Cancer Science

    Article Title: Methylation‐associated silencing of miR‐9‐1 promotes nasopharyngeal carcinoma progression and glycolysis via HK2

    doi: 10.1111/cas.15103

    Figure Lengend Snippet: MiR‐9‐1 is downregulated by promoter methylation in nasopharyngeal carcinoma (NPC). A, CpG islands in miR‐9‐1. The transcription start site (TSS) is indicated by a curved arrow. The regions analyzed by methylation‐specific PCR (MSP) and MassARRAY are shown. B, Relative miR‐9‐1 expression in normal nasopharyngeal NP69 cells and NPC cell lines. Glyceraldehyde‐3‐phosphate dehydrogenase ( GAPDH ) was used as the endogenous control. C, Relative miR‐9‐1 expression in 11 normal nasopharyngeal tissues (N) and 16 NPC tissues (T). U6 was used as the endogenous control. * P < .05. D, Quantitative MassARRAY methylation analysis of miR‐9‐1 in normal tissues (NT), NPC tissue (P), NP69 cell lines, NPC cell lines. E, F, MSP analysis of miR‐9‐1 promoter methylation in NPC cell lines and tissue specimens. M, methylated; U, unmethylated; L, marker; 1‐14, NPC tissue specimen numbers. G, Demethylation treatment with 5‐Aza‐2’‐deoxycytidine (DAC) restored the expression of miR‐9‐1 in NPC cell lines

    Article Snippet: The Sequenom MassARRAY platform (Agena Bioscience) was applied to examine the promoter methylation level of miR‐9‐1 quantitatively.

    Techniques: Methylation, Expressing, Marker

    During transforming growth factor β1 (TGFβ1)-induced epithelial-to-mesenchymal transition (EMT), stomatin was downregulated through methylation-dependent transcription mechanism. (A) Real-time polymerase chain reaction (PCR) was performed to validate the transcriptional change of stomatin identified in the microarray. **, P<0.001; (B) Two CpG islands spanning from −768 to −223 bp and from −143 to +122 bp upstream of STOM gene were identified by EMBOSS cpgplot program (upper). Schematic representation of −768/−223 and −143/+122 (marked with the grey square) CpG islands in the upstream of stomatin gene (lower). Red box marked the exon. The translation start site was position +1; (C) Measuring stomatin promoter methylation levels by Sequenom MassARRAY assay; (D) Sequenom MassARRAY analysis of methylation percentages of CpG sites at the stomatin promoter. The top panel showed the methylation percentages of 30 sites in human bronchial epithelial (HBE) and A549 cells. Dots with different color depths represent different methylation status. Dark dots represent high degrees of methylation. Light dots represent low degrees of methylation. The methylation percentages of 30 CpG sites were compared by two-tailed paired Student’s t test. In line graph, each dot represents an individual CpG dinucleotide. Green dots represent CpG dinucleotides in HBE cells. Red dots represent CpG sites in A549 cells. The corresponding detection sites were connected in a straight line. Real-time PCR was performed to evaluate the expression of stomatin in HBE and A549 cells (P<0.01); (E) The same sequenom MassArray and statistical analyses were also implemented to assess the methylation status of the indicated promoter region of stomatin in A549 and A549-5Aza cells (P<0.01); (F) A549 cells were exposed to TGFβ1 (5 ng/mL) for 2 d or 5 d with or without 5-Aza. Expression of DNMT3A and stomatin was analyzed by western blotting. β-actin was used as a loading control; (G) Sequenom MassArray analysis was implemented to assess the stomatin promoter methylation levels in A549, A549-TGFβ1, and A549-TGFβ1/5-Aza cells (P=0.005, P=0.004, respectively).

    Journal: Chinese Journal of Cancer Research

    Article Title: Stomatin plays a suppressor role in non-small cell lung cancer metastasis

    doi: 10.21147/j.issn.1000-9604.2019.06.09

    Figure Lengend Snippet: During transforming growth factor β1 (TGFβ1)-induced epithelial-to-mesenchymal transition (EMT), stomatin was downregulated through methylation-dependent transcription mechanism. (A) Real-time polymerase chain reaction (PCR) was performed to validate the transcriptional change of stomatin identified in the microarray. **, P<0.001; (B) Two CpG islands spanning from −768 to −223 bp and from −143 to +122 bp upstream of STOM gene were identified by EMBOSS cpgplot program (upper). Schematic representation of −768/−223 and −143/+122 (marked with the grey square) CpG islands in the upstream of stomatin gene (lower). Red box marked the exon. The translation start site was position +1; (C) Measuring stomatin promoter methylation levels by Sequenom MassARRAY assay; (D) Sequenom MassARRAY analysis of methylation percentages of CpG sites at the stomatin promoter. The top panel showed the methylation percentages of 30 sites in human bronchial epithelial (HBE) and A549 cells. Dots with different color depths represent different methylation status. Dark dots represent high degrees of methylation. Light dots represent low degrees of methylation. The methylation percentages of 30 CpG sites were compared by two-tailed paired Student’s t test. In line graph, each dot represents an individual CpG dinucleotide. Green dots represent CpG dinucleotides in HBE cells. Red dots represent CpG sites in A549 cells. The corresponding detection sites were connected in a straight line. Real-time PCR was performed to evaluate the expression of stomatin in HBE and A549 cells (P<0.01); (E) The same sequenom MassArray and statistical analyses were also implemented to assess the methylation status of the indicated promoter region of stomatin in A549 and A549-5Aza cells (P<0.01); (F) A549 cells were exposed to TGFβ1 (5 ng/mL) for 2 d or 5 d with or without 5-Aza. Expression of DNMT3A and stomatin was analyzed by western blotting. β-actin was used as a loading control; (G) Sequenom MassArray analysis was implemented to assess the stomatin promoter methylation levels in A549, A549-TGFβ1, and A549-TGFβ1/5-Aza cells (P=0.005, P=0.004, respectively).

    Article Snippet: The methylation status of Stomatin promoter was detected using Sequenom MassARRAY quantitative methylation analysis platform (BGI tech, Shenzhen, China).

    Techniques: Methylation, Real-time Polymerase Chain Reaction, Microarray, Sequenom Massarray Assay, Two Tailed Test, Expressing, Western Blot, Control